Literature DB >> 24156335

Wnt signaling in leukemias and myeloma: T-cell factors are in control.

Machteld M Tiemessen1, Frank J T Staal.   

Abstract

Aberrant activation of the Wnt pathway has been implicated in the pathogenesis of many malignancies, especially solid tumors. During the past decade it also became clear that in hematological malignancies abnormal regulation of the Wnt pathway can either be causative or enhance disease progression, which will be discussed in detail in this review.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24156335     DOI： 10.2217/fon.13.122

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  4 in total

1.  MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development.

Authors:  Sahar Harati; Lee A D Cooper; Josue D Moran; Felipe O Giuste; Yuhong Du; Andrei A Ivanov; Margaret A Johns; Fadlo R Khuri; Haian Fu; Carlos S Moreno
Journal:  PLoS One       Date:  2017-01-24       Impact factor: 3.240

2.  Splicing factor arginine/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication.

Authors:  Yuanjiao Zhang; Xichao Yu; Rongze Sun; Jie Min; Xiaozhu Tang; Zigen Lin; Siyuan Xie; Xinying Li; Shengfeng Lu; Zhidan Tian; Chunyan Gu; Lesheng Teng; Ye Yang
Journal:  Clin Transl Med       Date:  2022-02

3.  Discrete roles of canonical and non-canonical Wnt signaling in hematopoiesis and lymphopoiesis.

Authors:  F Famili; B A E Naber; S Vloemans; E F E de Haas; M M Tiemessen; F J T Staal
Journal:  Cell Death Dis       Date:  2015-11-19       Impact factor: 8.469

Review 4.  Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential.

Authors:  Ingrid Spaan; Reinier A Raymakers; Anja van de Stolpe; Victor Peperzak
Journal:  J Hematol Oncol       Date:  2018-05-18       Impact factor: 17.388
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.